The association of MEFV gene mutations with the disease risk and severity of systemic juvenile idiopathic arthritis

Table 1 Demographic and clinical characteristics of patients eligible for current study

	Patients included in current study (n = 57)
Onset age, median (IQR), years	6.42 (5.30)
Male, n (%)	28 (49.1%)
Time to initiation of therapy, median (IQR), months	1.00 (1.00)
Follow-up period, median (IQR), months	54.00 (75.00)
Number of the affected joints, median (IQR)	5 (11)
Manifestations, n (%)
Fever	57 (100%)
Skin Rash	50 (87.7%)
Joint Swelling or arthralgia	57 (100%)
Hepatomegaly	16 (28.1%)
Splenomegaly	24 (42.1%)
Lymphopathy	30 (52.6%)
Serositis	13 (22.8%)
MAS	6 (10.5%)
Lab examinnation^a
ESR (mm/h)	78.77 (30.63)
CRP (mg/L)	130.00 (109.83)
SF (ng/ml)	1376.00(2670.00)
WBC (×10^9/L)	16.14 (11.91)
PLT (×10^9/L)	444 (194)

Abbreviation: IQR interquartile range, MAS macrophage activation syndrome, ESR erythrocyte sedimentation rate, CRP C reactive protein, SF serum Ferritin, WBC white blood cells; PLT platelets
^aThe data of ESR is represented in mean(S.D.), while other laboratory items in median (IQR)

ISSN: 1546-0096